Given the size of the SARS-CoV-2 virion, it is not expected to traverse a healthy glomerular filtration barrier, so proximal tubular cell entry via ACE2 would require either the disruption of the glomerular filtration barrier (e.g., glomerulopathy) or tubular injury (e.g., AKI) that disrupts the continuity of the tubular epithelial layer or alters the localization of ACE2 expression. The gene discussed is ACE2; the disease is lipoprotein glomerulopathy.